PSR Orphan Experts, Raremark announce rare disease tieup

London cityscape
London cityscape

The Netherlands-based orphan drug consulting and research company PSR Orphan Experts has signed a pact with Raremark, a new online service for families affected by rare disease, on a partnership designed to speed up the development of new treatments.

This new collab will use the companies’ complementary experience and capabilities to address the unique challenges involved in clinical research in orphan indications--which typically struggles with patient recruitment, given the small patient population for rare diseases.

London’s Raremark said it will engage families in the clinical trial process, helping them understand what taking part in a study means, and keeping them informed while participating in one.


Webinar: Optimizing Oncology Trials with a ctDNA Test Custom-Built for MRD and Molecular Monitoring

Join this webinar to discover the advantages of using Signatera™ (RUO), a novel assay custom-designed for each patient that detects circulating tumor DNA (ctDNA) with high sensitivity and specificity to monitor molecular residual disease, early recurrence, and treatment response across solid tumors.

Meanwhile PSR will provide strategic and operational consulting, in addition to its traditional CRO services.

“Most of the 7,000 known rare diseases lack approved drugs, meaning that clinical trials may be the only opportunity for people affected to access treatments,” said Roger Legtenberg, CEO of PSR.

“The rare disease community is generally very active, but there is a need for increased awareness that clinical trials are an option. We believe Raremark’s approach of engaging rare disease patients and families will bring benefits for all involved in drug development.”

Julie Walters, Raremark’s founder, added: “We’re impressed by PSR’s genuine commitment to the patient community, its sole focus on orphan disease, and the high caliber of its management team and long-standing relationships with specialist research centers.”

-check out the release

Suggested Articles

Thermo Fisher Scientific has moved to acquire viral vector developer and manufacturer Brammer Bio for $1.7 billion in cash.

French biotech AlzProtect has teamed up with CRO Parexel for its midstage test of AZP2006 in patients with progressive supranuclear palsy.

WIRB-Copernicus launched a product aimed at upping the efficiency of clinical research operators at institutions and independent research sites.